In HCC cells, overexpression of MVP reduced sensitivity to epidermal growth factor receptor (EGFR) inhibitor gefitinib, enhanced AKT phosphorylation, and lowered the expression of genes associated with inflammatory pathways. The gene discussed is EGFR; the disease is hepatocellular carcinoma.